home All News open_in_new Full Article

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD

Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation Presentation featuring network meta-analysis of SYMBRAVO® versus oral CGRPs NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system […]


today 20 h. ago attach_file Other

attach_file Economics
attach_file Events
attach_file Society
attach_file Politics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Culture
attach_file Other
attach_file Transport
attach_file Other
attach_file Politics
attach_file Economics
attach_file Culture
attach_file Politics
attach_file Politics
attach_file Other
attach_file Economics
attach_file Technology


ID: 2365100872
Add Watch Country

arrow_drop_down